

Article

Autoantibody Profiling in Plasma of Dengue Virus–Infected Individuals

Hoa Thi My Vo ¹, Veasna Duong ², Sowath Ly ³, Quan-Zhen Li ⁴, Philippe Dussart ² and Tineke Cantaert ^{1,*}

¹ Immunology Unit, Institut Pasteur du Cambodge, Institut Pasteur International Network, 5 Monivong Blvd., Phnom Penh 12201, Cambodia; tvo@pasteur-kh.org

² Virology Unit, Institut Pasteur du Cambodge, Institut Pasteur International Network, 5 Monivong Blvd., Phnom Penh 12201, Cambodia; dveasna@pasteur-kh.org (V.D.); pdussart@pasteur-kh.org (P.D.)

³ Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Institut Pasteur International Network, 5 Monivong Blvd., Phnom Penh 12201, Cambodia; lsowath@pasteur-kh.org

⁴ Department of Immunology and Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA; Quan.Li@UTSouthwestern.edu

* Correspondence: tineke.cantaert@pasteur.fr; Tel.: +855-95796225

Received: 15 September 2020; Accepted: 3 December 2020; Published: 18 December 2020



Abstract: Dengue is an arboviral disease caused by dengue virus (DENV) with high prevalence in tropical and sub-tropical regions. Autoimmune syndromes following dengue can be observed in long term follow up. Anti-DENV antibodies are cross-reactive with surface antigens on endothelial cells or platelets and could be involved in the pathogenesis of dengue. However, no studies have analyzed the autoantibody repertoire and its roles in dengue pathogenesis. Hence, we aimed to describe the autoantibody profile in dengue patients with different disease severities. We utilized a protein array with 128 putative autoantigens to screen for IgM and IgG reactivity in plasma obtained from healthy donors ($n = 8$), asymptomatic individuals infected with DENV ($n = 11$) and hospitalized dengue patients ($n = 21$). Even though the patient cohort is small, we show that 80 IgM and 6 IgG autoantibodies were elevated in DENV infected patients compared to age-matched healthy donors. Individuals undergoing a primary DENV infection showed higher amounts of IgG autoantibodies, not IgM autoantibodies, compared to individuals undergoing secondary infection. No differences were observed between asymptomatic and hospitalized dengue patients. Nineteen autoantibodies, which react against several coagulation and complement components, correlated with platelet counts in severe dengue patients. This current study provides a framework to explore a possible role of candidate autoantibodies in dengue immunopathogenesis.

Keywords: dengue; autoantibody; infectious disease

1. Introduction

Dengue virus (DENV) is a member of the family Flaviviridae, and consists of four distinct DENV serotypes, DENV-1 to DENV-4 [1]. An estimated 390 million individuals are infected by DENV each year, of which ~25% are symptomatic [2]. Disease severity ranges from inapparent infection to classic dengue fever (DF) to dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). DHF/DSS occurs almost exclusively in patients re-infected with a different dengue serotype where hemorrhage, thrombocytopenia, vascular leakage and shock are the major clinical signs and possible cause of death in those patients [3,4]. Currently, no specific treatment is available for dengue.

Proposed mechanisms to explain immunopathogenesis include the development of a skewed T cell responses leading to cytokine storm and/or the existence of pre-existing, non-neutralizing

antibodies causing antibody-dependent enhancement [5]. During the acute phase of infection, a rapidly expanding plasmablast population has been observed, where plasmablast frequencies are increased compared to other infectious diseases or after influenza or yellow fever vaccination [6,7]. In addition, frequencies of circulating plasmablast are associated to more severe dengue disease [8]. Here, DENV is capable to activate B cells directly inducing polyclonal and highly cross-reactive antibody generation after both primary and secondary infection [9–12]. In steady state, polyreactive and autoreactive B cells are deleted from the mature naïve B cell repertoire at discrete checkpoints; however, these checkpoints could be defective in patients infected with DENV [13,14]. Indeed, a deregulated T cell compartment and increased circulating cytokine concentrations as observed during acute DENV infection could lead to the development of autoreactive antibodies [15,16]. This increased plasmablast population observed during DENV infection may contribute to the production of low affinity, cross-reactive and possible autoreactive antibodies.

Infection with Zika virus (ZIKV), a flavivirus closely related to DENV, has been reported to be associated with Guillain-Barre syndrome, an autoimmune disease caused by anti-ganglioside and anti-glycolipid antibodies [17–21]. Compared to healthy donors, patients infected with DENV had an overall higher risk to develop autoimmune diseases during long-term follow up such as multiple sclerosis, myasthenia gravis, autoimmune encephalomyelitis, systemic vasculitis, systemic lupus erythematosus, and others [22]. In contrast, a recent study in Taiwan observed a lower risk of primary Sjogren's syndrome in previous patients infected with DENV [23]. Two years after infection, patients with long-term persistence of symptoms showed altered autoimmune markers compared to asymptomatic infected individuals [21]. Thus, accumulating evidence suggest that DENV infection may have long-term effects priming individuals to autoimmune diseases.

A variety of autoantibodies against host factors such as endothelial cells, platelets and components in coagulation pathways were observed in plasma of patients infected with DENV during the acute phase and up to 8 months after infection [24–27]. Plasma from patients infected with DENV could enhance activation of endothelial cells and platelets resulting in disturbing their physiological functions [28,29]. Indeed, increased anti-platelet autoantibody levels in patients infected with DENV were associated with acute secondary infection [30] and dengue severity [27]. Moreover, autoantibodies against viral non-structural protein 1 (NS1) are detected early after DENV infection and NS1-specific antibodies are cross-reactive with blood clotting proteins and endothelial cell antigens, and are hypothesized to contribute to manifestation in DHF/DSS patients [24,29,31,32]. Recently, it has been shown that both patients infected with DENV and DENV NS1-immunized rabbits produced antibodies against TACI, BCMA, and BAFFR, which are receptors expressed on B cells important for B cell maturation and survival. In a dengue mouse model, these antibodies suppressed DENV neutralizing antibody formation [33].

Taken together, it has been suggested that autoantibodies could be involved in the pathogenesis of dengue; however, a systematic screen of autoantibody reactivities during the acute phase of DENV infection has not been performed. Therefore, we utilized a proteomic microarray, which has the capacity to hold large number of self-antigens on a solid surface, to screen plasma from patients with different disease severity at early convalescence, 6–10 days after laboratory-confirmed DENV infection. Even though the patient cohort is small, we show that 80 IgM autoantibodies were elevated in patients infected with DENV compared to age-matched healthy donors, indicating general immune activation after viral infection. Presence of IgG autoantibodies against several components of the complement pathway such as Factor P and Complement C4, and coagulation pathways such as Prothrombin protein were correlated with platelet counts in DHF patients. These findings provide an exploratory analysis of autoantibody profiles in DENV infection and its association with disease severity.

2. Results

2.1. Characteristics of the Study Population

A total of 40 Cambodian children were included in the study. Of these, eight were healthy donors (HD) and 32 were individuals infected with DENV. DENV infection was confirmed by detection of viral RNA in the serum and measured as copies/mL (Table 1). Of the dengue patients, 21 patients were hospitalized and 11 individuals were undergoing asymptomatic infection (ASD). Here, asymptomatic individuals were identified via a household-based cluster investigation conducted around confirmed DENV-infected cases [34]. The demographic information and laboratory characteristics from the patients are summarized in Table 1. DENV serotypes were identified by serotype-specific reverse transcription-qPCR (RT-qPCR) and showed that DENV-1 was the most prevalent serotype. The patients, who were admitted at the hospital at 3 ± 2 days after the onset of symptoms, were classified as dengue fever (DF; $n = 13$) and dengue hemorrhagic fever (DHF; $n = 8$) according to the WHO 1997 guidelines [35]. Six individuals were undergoing primary infection and twenty-six individuals were undergoing secondary DENV infection. As expected, platelet counts were lower in patients with DHF compared to patients with DF (Table 1).

Table 1. Demographic and clinical characteristics of the study population.

Characteristics	HD ($n = 8$)	ASD ($n = 11$)	DF ($n = 13$)	DHF ($n = 8$)	<i>p</i> -Value
Age (year)	8.9 ± 5.6	11.5 ± 3.1	9.9 ± 3.0	10.1 ± 2.9	0.4 ^a
Sex ($n, \%$)					0.3 ^b
Female	4 (50%)	3 (30%)	7 (53.9%)	5 (62.5%)	
Day of Fever (day)	NA	NA	7.3 ± 0.8	7.1 ± 0.8	0.8 ^c
Temp (°C)	NA	NA	37.6 ± 1	36.9 ± 0.4	0.1 ^c
Pulse (bpm)	NA	NA	100 ± 15	96 ± 14	0.6 ^c
Systolic Blood Pressure (mmHg)	NA	NA	100 ± 10	98 ± 10	0.8 ^c
Diastolic Blood Pressure (mmHg)	NA	NA	63 ± 11	63 ± 9	0.8 ^c
Hematocrit (%)	NA	NA	38.5 ± 3.9	43.1 ± 4.8	0.05 ^c
Platelets ($10^9/l$)	NA	NA	149 ± 96	61 ± 38	0.003 ^c
Viral Load (Log ₁₀ copy/mL)	NA	1.17×10^3	4.65×10^4	6.21×10^4	0.02 ^a
Serotype (n)					
DENV-1	NA	8 (72.73%)	10 (76.9%)	7 (87.5%)	
DENV-2	NA	2 (18.18%)	0 (0%)	1 (12.5%)	
DENV-4	NA	1 (9.09%)	2 (15.4%)	0 (0%)	
Undetermined		0 (0%)	1 (7.7%)	0 (0%)	
Type of Infection ($n, \%$)					
Primary Infection	NA	3 (27.3%)	3 (23.1%)	0 (0%)	
Secondary Infection	NA	8 (72.7%)	10 (76.9%)	8 (100%)	

HD: healthy controls, ASD: asymptomatic individuals infected with DENV, DF: dengue fever, DHF: dengue hemorrhagic fever. NA: not applicable; ^a: *p*-values were calculated using ANOVA test. ^b: *p*-values were calculated using Chi-square test. ^c: *p*-values were calculated using Mann-Whitney test.

2.2. Autoantibody Profiles in DENV-Infected Patients

Antibodies against self-antigens such as platelets, endothelial cells and molecules from the coagulation pathway have been detected in patients infected with DENV [23,25,26]. In current study, an antigen array was used for high-throughput autoantibody profiling in patient plasma. The array consists of 123 putative autoantigens, containing a variety of proteins related to nuclear proteins, basement membrane proteins, cell stress-related proteins and others [36]. In the microarray, the binding of autoantibodies to each antigen spotted on nitrocellulose coated slide resulted in a fluorescence signal. The normalized fluorescence intensity (NFI) of each antigen was quantified and shown (Supplementary Figure S1). We analyzed plasma at 6–10 days after PCR-confirmed DENV infection, as we reasoned that at this time point sufficient amounts of potential autoantibodies would be present in circulation for detection.

Viral infections are known to induce polyclonal B cell stimulation and bystander activation [10,37–39]. Therefore, we first investigated the presence of autoantibodies in patients infected with DENV compared to HD. Figure 1A,B displays the heatmaps where autoantibody expression is ordered from lowest to highest (blue: low expression, yellow: high expression). Significantly, higher NFI of IgM autoantibodies can be observed in patients infected with DENV compared to HD, whereas the NFI of IgG autoantibodies was comparable between both groups (Figure 1C,D). Furthermore, to distinguish the autoantibody profiles elicited in patients infected with DENV and HD, the NFI of each autoantibody was compared. Eighty IgM and six IgG autoantibodies were identified that had increased NFI in DENV-infected patient sera compared to HD (Supplementary Figure S2A,B). Among these eighty IgM autoantibodies, patients infected with DENV exhibited increased NFI against β 2-glycoprotein-I (β 2GPI) and protein components in the complement pathway such as C5, C8, C9 and factor B compared to HD. Interestingly, both IgM and IgG autoantibodies against factor H and factor P were present in patients infected with DENV compared to healthy controls. Taken together, our findings suggest that individuals produce a variety of autoantibodies, especially, IgM autoantibodies, shortly after DENV infection, which is probably due to bystander activation of circulating memory B cells [10,12,40,41].




Figure 1. Distinct autoantibody profiles between healthy donors (HD) and DENV-infected individuals. (A,B) In the heatmaps, each row shows the average NFI of IgM or IgG autoantibodies of each group. The colors represent values of NFI of autoantibodies. (C,D) Each dot represents the sum of NFI signals of IgM autoantibodies or IgG autoantibodies in each individual. The dashed lines indicate the baseline of the median NFI in HD group. Statistical analysis was done using two-tailed Mann–Whitney tests to compare the two groups. Median and interquartile ranges are shown. ** $p < 0.01$. HD = 8, DENV = 32.

2.3. Increased IgG Autoantibody NFI Are Associated with Primary DENV Infection

As immune status to DENV is an important determinant for the humoral response to DENV [7,41–44], we aimed to understand if a secondary infection would also lead to an altered production of autoantibodies. Therefore, we stratified our patient cohort in primary and secondary infected individuals, yielding only 6 individuals in the primary infected group. A limitation here is that subjects in the primary infected group were all male and infected by DENV-1, whereas in the secondary infected group only 42% were male and 73% were infected with DENV-1, which could bias the data.

Here, the IgM and IgG autoantibody NFI was higher in primary infected patients compared to patients undergoing secondary infection (Figure 2A,B). When compared to the total NFI generated by each individual, the NFI of IgG antibodies in patients with primary infection was significantly higher than in patients with secondary infection (Figure 2C,D). Furthermore, to distinguish the autoantibody profiles, the NFI of each autoantibody was compared. Fifteen IgM and seventy IgG autoantibodies were identified that had increased NFI in primary DENV-infected patient sera compared to secondary infected sera (Supplementary Figure S3A,B).




Figure 2. Comparison of expression of autoantibodies between primary and secondary DENV infection. (A,B) In the heatmaps, each row shows the average NFI of IgM or IgG autoantibodies in each group. The colors represent values of NFI of autoantibodies. (C,D) Each dot represents the sum of NFI signals of IgM autoantibodies or IgG autoantibodies in each individual. The dashed lines indicate the baseline of the median NFI in the HD group. Statistical analysis was done using two-tailed Mann–Whitney tests to compare two groups. Median and interquartile ranges are shown. ** $p < 0.01$. Primary DENV infection = 6, Secondary DENV infection = 26.

2.4. Decreased Autoantibodies Correlate with Severity

While primary DENV infections mostly lead to inapparent or mild disease symptoms, secondary infections can cause a wide range of disease symptoms from classical DF to DHF or DSS [45–47]. Hospitalized patients infected with DENV are characterized by higher serum anti-DENV IgM concentrations, activation of B cell response and increased plasma cell development compared to asymptomatic infected patients [34]. Hence, we aimed to investigate whether disease severity could be associated to the development of autoantibodies during infection. Therefore, IgG and IgM autoantibody profiles in patients with secondary DENV infection and with different disease severity classified according to WHO 1997 criteria were analyzed. No differences in the NFI of total autoantibodies were found between asymptomatic infected individuals and hospitalized patients (Figure 3A,B) or in DF patients compared to DHF patients (Supplementary Figure S5). However, analyzing the NFI of individual antibodies, we identified four IgM and fourteen IgG autoantibodies that showed decreased NFI in DF/DHF patients compared to asymptomatic infected individuals (Supplementary Figure S4A,B). Those antibodies bind to extracellular and intracellular matrix proteins such as heparan sulfate, proteoglycan and mitochondrial-associated proteins.





Figure 3. Autoantibody expression in secondary DENV infection. (A,B) Each dot represents the sum of NFI signals of IgM autoantibodies or IgG autoantibodies in each individual. The dashed lines indicate the baseline of the median NFI in HD group. Statistical analysis was done using two-tailed Mann–Whitney tests to compare the two groups. Median and interquartile ranges are shown. ASD = 8, DF/DHF = 18.

Thrombocytopenia is one of the key features of severe dengue disease. As expected, the platelet count in DHF patients was significantly lower compared to DF patients (Figure 4A). Among the 123 IgG autoantibodies, 19 of them positively correlated with platelet counts in DHF patients (Figure 4B). For example, it was observed that low amounts of anti-factor P IgG and anti-complement C4 were associated with low platelet counts in DHF patients. Other antibodies associated with platelet count are antibodies against nuclear proteins, such as KU (P70/P80) DNA-binding antigen, Smith antigen, histone antigen and nucleosome antigen. Taken together, these data suggest the presence of a subset of IgG autoantibodies in individuals infected with DENV that required hospitalization.



IgG Autoantibody	r	p value
KU (P70/P80)	0.8333	*
SmD	0.8333	*
SRP54	0.8333	*
Histone H3	0.8264	*
M2	0.8095	*
Vitronectin	0.8095	*
PR3	0.791	*
complement C4	0.7857	*
Histone H4	0.7857	*
Prothrombin protein	0.7807	*
MPO	0.7619	*
Sm/RNP	0.7619	*
SmD1	0.7619	*
Factor P	0.7563	*
Alpha Fodrin (SPTAN1)	0.7425	*
CRP antigen	0.7381	*
Mi-2	0.7381	*
Nucleosome antigen	0.7381	*
U1-snRNP-C	0.7381	*

Figure 4. Autoantibody expression correlates with platelet counts. (A) The graph shows the platelet count in patients infected with DENV. Statistical analysis was done using two-tailed Mann–Whitney tests to compare the two groups. Median and interquartile range are shown. (B) The table presents the IgG autoantibodies in DHF patients that correlated with platelet count. Non-parametric Spearman test was used for correlation analyses. * $p < 0.05$, ** $p < 0.01$. DF = 10 and DHF = 8.

3. Discussion

In current study, we have screened 32 dengue-infected patients with variable disease severity for the development of autoantibodies in the early convalescent phase by protein array containing 128 autoantigens. Even though the patient cohort is small, we show that 80 IgM and 6 IgG autoantibodies were elevated in DENV infected patients compared to age-matched healthy donors. Individuals undergoing a primary DENV infection showed higher amounts of IgG autoantibodies, not IgM autoantibodies, compared to individuals undergoing secondary infection. No differences were observed between asymptomatic and hospitalized dengue patients. Nineteen autoantibodies,

which react against several coagulation and complement components, correlated with platelet counts in severe dengue patients.

Various viral diseases induce transient autoantibodies during infection. The mechanism underlying the production of autoantibodies could be due to molecular mimicry, the presence of superantigens, epitope spreading and polyclonal activation due to the inflammatory milieu [48]. These antibodies could be directly involved in exacerbation or protection from severe disease or they could be mere a bystander effect of general immune activation and inflammation. They could have a role in possible clearance of virus and virus-infected cells, interfere with the binding of the virus to the host cell or could participate in the immune response through immune-complex formation and antigen clearance [48–50].

In patients infected with DENV, B cells show an activated phenotype leading to massive early plasmablast formation [8,11,51]. The current study demonstrates that eighty different IgM autoantibodies against complement components, coagulation factors and intracellular antigens were increased in patients infected with DENV compared to HD. These IgM autoantibodies may be generated from early-activated plasmablasts and could reflect bystander activation of the B cell compartment [10,37,39].

Serum-induced platelet lysis was observed in patients infected with DENV but not in patients infected with other members of the Flaviviridae family such as Japanese encephalitis virus and hepatitis C virus, or enterovirus A71 [27]. Here, we show the detection of IgM autoantibodies against platelets in patients infected with DENV. Interestingly, during DENV infection, IgM and IgG antibodies against NS1 protein can be detected which are cross-reactive with platelet antigens [32,52] and their presence correlate with disease severity [27,52].

We observed that patients infected with DENV exhibited higher levels of IgM autoantibody against β 2GPI compared to HD, which is in parallel with findings in other infectious diseases such as in patients with HIV, syphilis, leprosy and hepatitis C [53] or in patients with autoimmune thrombotic disorder [54]. Anti- β 2GPI IgG binds to cell surface molecules of endothelial cells, platelets and immune cells thereby resulting in cell activation [54]. Further studies are needed to clarify whether by targeting platelet cells and endothelial cells, β 2GPI autoantibodies could contribute to dengue pathogenesis.

In the current study, a variety of autoantibodies targeting components of the complement pathway such as C5, C8, C9, factor B, factor H and factor P were detected in patients infected with DENV compared to HD. A robust activation of the complement pathways is suggested to contribute to damage of blood vessel cells and initiation of vascular leakage in DENV infection. While factor H inactivates the alternative C3 convertase (C3bBb) complex leading to inhibition of the alternative complement pathway, factor P has a role in stabilizing the complex, thereby enhancing activation of the alternative complement pathway [55]. It has been reported that compared to DF patients, DHF patients had a lower expression of factor H, following increased formation of C3bBb complex promoting the alternative complement cascade. IgG autoantibodies against factor H and factor P were present in patients infected with DENV compared to healthy controls. Furthermore, amounts of IgG autoantibodies against factor H and factor P were higher in individuals with primary infection than those in secondary infection. As expected, the platelet count was lower in DHF patients compared to DF patients. Interestingly, low amounts of anti-factor P IgG, anti-prothrombin IgG and anti-complement C4 IgG were associated with low platelet counts in DHF patients, whereas such association was not observed in DF patients. This might reflect an increased clearance of these autoantibodies through immune complex formation with C4 and factor P, contributing to the imbalance in the complement cascade, promoting DHF progression. In addition to complement and coagulation proteins, many autoantibodies targeting extracellular and intracellular matrix proteins such as heparan sulfate, proteoglycan and mitochondrial antigens were decreased in DF/DHF patients compared to individuals with ASD. Heparan sulfate moieties of proteoglycans are a putative receptor for DENV [56]. Therefore, anti-heparin sulfate antibodies might interfere with DENV attachment to cell membranes and thereby block subsequent infection.

Besides anti-factor P IgG and anti-complement C4, other IgG autoantibodies were found associated with platelet count in DHF patients. Those antibodies bind nuclear proteins, such as KU (P70/P80)

DNA-binding antigen, Smith antigen, histone antigen and nucleosome antigen, which are prevalent in autoimmune disorders [57].

Secondary DENV infection induces a rapid increase in DENV-specific IgGs compared to primary infection [12,58]. Here, we detected higher amounts of IgG autoantibodies in individuals undergoing a primary DENV infection compared to individuals undergoing secondary infection. The presence of IgG autoantibodies reflects leakiness in tolerance mechanisms, allowing the maturation of autoantigen-binding B cells and their subsequent differentiation into antibody-secreting plasma cells [59].

The relationship between autoimmunity and infection has been debated for a long time. On one hand, the presence of autoimmunity can enhance infection. For example, patients with primary Sjogren's syndrome showed 14% higher chance to experience hepatitis C infection than healthy controls; and those patients had a higher prevalence of hepatic manifestations [60]. On the other hand, many infection can cause the transient development of autoimmunity [48]. How long the detected autoantibodies last after the infection is unknown as we do not have follow-up samples of these individuals. Another caveat of our study is the limited sample size, therefore our study lacks power to detect small differences. In addition, due to the low amount of plasma available, we were unable to perform any cross-validation experiments. Therefore, further studies are still needed to address these remaining concerns and questions.

This exploratory study profiles developing autoantibodies in patients infected with DENV using autoantigen microarray. We observed that patients infected with DENV had higher levels of IgM autoantibodies than HD, indicating a general immune activation after viral infection. Higher amounts of IgG autoantibodies were detected in patients undergoing primary infection compared to secondary infection. Whereas no differences were observed between asymptomatic and hospitalized patients infected with DENV, reduced platelet count in severe patients infected with DENV was correlated to lower amounts of several autoantibodies. Current study provides preliminary data to further explore a possible role of candidate autoantibodies in dengue pathogenesis.

4. Materials and Methods

4.1. Ethics Statement

The ethical approval and recruitment of patients for this study has been described before [34,61]. Ethical approval for the study was obtained from the National Ethics Committee of Health Research of Cambodia. Written informed consent was obtained from all participants or the guardians of participants under 18 years of age before inclusion in the study.

4.2. Patient Samples

Hospitalized dengue cases were identified from patients presenting with acute dengue-like illness between June and October of 2012 and 2013 at Kampong Cham City Provincial Hospital and two district hospitals in Kampong Cham province. Plasma specimens were tested for DENV infection at the Institut Pasteur du Cambodge, the reference center for arboviral diseases in Cambodia. Patients were diagnosed as acute DENV-infected as following: a positive RT-qPCR [50] or NS1 positive by rapid test (SD Bioline Dengue Duo kits from Standard Diagnostics, Abbott, Chicago, IL, USA) at hospital admission, or seroconversion from DENV-IgM negative to IgM positive during the hospital stay (admittance and discharge sample). Platelet counts and hematocrit were determined by complete blood count at hospital admittance and patients were classified for severity according to WHO 1997 criteria upon discharge [35]. In total, 21 plasma samples from DENV-positive patients at hospital discharge were included in this study (Table 1). A cluster investigation was initiated, enrolling all family members in the household and people living within a 200-m radius of the home of the hospitalized dengue cases [61]. Here, individuals were diagnosed as acute DENV-infected by RT-qPCR at time of blood sampling. Individuals were questioned about history of symptoms 4 days before and were followed

up until 10 days after sampling for the occurrence of symptoms (including but not limited to fever, rash, headache, retro-orbital pain). The blood samples from those individuals without any symptoms but positive for DENV detection were collected at day 0 (D0) as the day positive-DENV detection and day 7. In addition, age- and sex-matched negative DENV individuals ($n = 8$) from the cluster-based investigation were included as healthy control.

4.3. Protein Microarray

IgG and IgM autoantibodies against 123 antigens were measured using an autoantigen microarray platform developed by University of Texas Southwestern Medical Center (<https://microarray.swmed.edu/products/category/protein-array/>). Briefly, plasma samples were retreated with DNases-I to remove free DNA and then diluted 1:50 in PBST buffer for autoantibody profiling. The autoantigen array bearing 123 autoantigens and 4 control proteins were printed in duplicates onto Nitrocellulose film slides (Grace Bio-Labs). The diluted serum samples were incubated with the autoantigen arrays, and autoantibodies were measured with cy3-conjugated anti-human IgG (1:2000, Jackson ImmunoResearch Laboratories) and cy5-conjugated anti-human IgM (1:2000, Jackson ImmunoResearch Laboratories), using a Genepix 4200A scanner (Molecular Device) with laser wavelengths of 532 and 635 nm. The resulting images were analyzed using Genepix Pro 7.0 software (Molecular Devices). The median of the signal intensity for each spot was calculated and the background around the spot was subtracted, and data obtained from duplicate spots were averaged. The background subtracted signal intensity of each antigen was normalized to the average intensity of the human IgG or IgM, which were spotted on the array as internal controls. Finally, the normalized fluorescence intensity (NFI) for each antigen was calculated by subtracting a PBS control which was included for each experiment as negative control. Signal-to-noise ratio (SNR) was used as a quantitative measurement of the true signal above background noise. SNR values equal to or greater than three were considered significantly higher than background, and therefore true signals. The NFI of each autoantibody was used to generate heatmaps using Cluster and Treeview software (Version 3) (<http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm>). Each row in the heatmap represents an autoantibody and each column represents a sample. Yellow color represents the signal intensity higher than the mean value and blue color means signal intensity is lower than the mean value. Grey or black color indicates the signal is close or equal to the mean value of the row.

4.4. Statistical Analysis

Data were analyzed and plotted using GraphPad Prism, version 7.0. The data were tested and did not pass the D'Agostino-Pearson normality test. Therefore, all group comparisons were performed with a non-parametric Mann-Whitney test or Chi2-test/Fisher's exact test as indicated. Demographic and clinical continuous data were expressed as the mean \pm SD while nominal data were presented as percentage (%) in the table. Median value and interquartile range of the data were shown in the scatter plots. Non-parametric Spearman's method was used for correlation analyses. To compare the autoantibody patterns between the groups, the multiple t-test analysis was applied. Statistical significance was assumed at $p < 0.05$.

Supplementary Materials: The following are available online at <http://www.mdpi.com/2076-0817/9/12/1060/s1>, Supplementary Figure S1. Analysis of autoantibody microarray data. Supplementary Figure S2. The graphs show the p -values in the multiple t -test comparisons of IgM or IgG autoantibodies in healthy controls compared with those infected with DENV. Supplementary Figure S3. The graphs show the p -values in the multiple t -test comparisons of IgM or IgG autoantibodies in primary individuals infected with DENV compared with those in secondary individuals infected with DENV. Supplementary Figure S4. The graphs show the p -values from multiple t -test comparisons of IgM or IgG autoantibodies in ASD compared with those in DF/DHF patients. Supplementary Figure S5. The graphs show autoantibody expression in DF and DHF patients with secondary DENV infection.

Author Contributions: T.C. designed the study. Q.-Z.L. performed the microarray experiment. H.T.M.V. analyzed and interpreted the data. V.D., S.L. and P.D. included patients, coordinated clinical data management and classified

patients according to WHO1997 criteria. H.T.M.V. and T.C. wrote the manuscript. V.D., P.D., H.T.M.V., Q.-Z.L. and S.L. edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: T.C. was funded by the Institute Pasteur International Network and is a HHMI-Wellcome Trust International Research Scholar (208710/Z/17/Z). Sample collection from patients infected with DENV was supported by the European Union Seventh Framework Program (FP7/2007–2011).

Acknowledgments: We thank all the patients who accepted to participate in the study, the doctors and nurses of the three hospitals in Kampong Cham province for patient enrolment and sample collection, and Rekol Huy from the National Dengue Control Program.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Katzelnick, L.C.; Fonville, J.M.; Gromowski, G.D.; Arriaga, J.B.; Green, A.; James, S.L.; Lau, L.; Montoya, M.; Wang, C.; Van Blargan, L.A.; et al. Dengue viruses cluster antigenically but not as discrete serotypes. *Science* **2015**, *349*, 1338–1343. [[CrossRef](#)]
- Wilder-Smith, A.; Ooi, E.E.; Horstick, O.; Wills, B. Dengue. *Lancet* **2019**, *393*, 350–363. [[CrossRef](#)]
- Guzmán, M.G.; Kouri, G.; Valdes, L.; Bravo, J.; Alvarez, M.; Vazques, S.; Delgado, I.; Halstead, S.B. Epidemiologic Studies on Dengue in Santiago de Cuba, 1997. *Stud. Financ. Adm. Athens* **2000**, *152*, 793–799. [[CrossRef](#)] [[PubMed](#)]
- Sangkawibha, N.; Rojanasuphot, S.; Ahandrik, S. Risk factors in dengue shock syndrome: A prospective epidemiologic study in Rayong, Thailand. *Public Health* **1984**, *107*, 357–361. [[CrossRef](#)]
- Harris, E. Dengue. *Lancet* **2015**, *385*, 453–465.
- Wrammert, J.; Onlamoon, N.; Akondy, R.S.; Perng, G.C.; Polsrila, K.; Chandele, A.; Kwissa, M.; Pulendran, B.; Wilson, P.C.; Wittawatmongkol, O.; et al. Rapid and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection in Humans. *J. Virol.* **2012**, *86*, 2911–2918. [[CrossRef](#)]
- Salje, H.; Cummings, D.A.T.T.; Rodriguez-Barraquer, I.; Katzelnick, L.C.; Lessler, J.; Klungthong, C.; Thaisomboonsuk, B.; Nisalak, A.; Weg, A.; Ellison, D.; et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. *Nature* **2018**, *557*, 719–723. [[CrossRef](#)]
- Upasani, V.; Vo, H.T.M.; Ung, S.; Heng, S.; Laurent, D.; Choeung, R.; Duong, V.; Sorn, S.; Ly, S.; Rodenhuis-Zybert, I.A.; et al. Impaired antibody-independent immune response of b cells in patients with acute dengue infection. *Front. Immunol.* **2019**, *10*, 2500. [[CrossRef](#)]
- Priyamvada, L.; Cross-reactive, D.H.; Plasmablasts, M. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts. *J. Virol.* **2016**, *90*, 5574–5585. [[CrossRef](#)]
- Ramon, A.; Correa, V.; Carolina, A.; Rosa, E.; Papa, P.; Theresa, A.; De Morais, S.; Maria, L.; Peçanha, T. Dengue Virus Directly Stimulates Polyclonal B Cell Activation. *PLoS ONE* **2015**, *10*, e0143391.
- Upasani, V.; Vo, H.T.; Auerswald, H.; Laurent, D.; Heng, S.; Duong, V.; Rodenhuis-zybert, I.A.; Dussart, P.; Cantaert, T. Direct infection of B cells by dengue virus modulates B cell responses in a Cambodian paediatric cohort. *Front. Immunol.* **2020**, in press.
- Balakrishnan, T.; Bela-ong, D.B.; Toh, Y.X.; Flaman, M.; Devi, S.; Koh, M.B.; Hibberd, M.L.; Ooi, E.E.; Low, J.G.; Leo, Y.S.; et al. Dengue Virus Activates Polyreactive, Natural IgG B Cells after Primary and Secondary Infection. *PLoS ONE* **2011**, *6*, e29430. [[CrossRef](#)] [[PubMed](#)]
- Cantaert, T.; Schickel, J.N.; Bannock, J.M.; Ng, Y.S.; Massad, C.; Delmotte, F.R.; Yamakawa, N.; Glauzy, S.; Chamberlain, N.; Kinnunen, T.; et al. Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint. *J. Clin. Investig.* **2016**, *126*, 4289–4302. [[CrossRef](#)]
- Wardemann, H.; Yurasov, S.; Schaefer, A.; Young, J.W.; Meffre, E.; Nussenzweig, M.C. Predominant autoantibody production by early human B cell precursors. *Science* **2003**, *301*, 1374–1377. [[CrossRef](#)]
- Menard, L.; Cantaert, T.; Chamberlain, N.; Tangye, S.G.; Riminton, D.S.; Church, J.A.; Klion, A.D.; Cunningham-Rundles, C.; Nichols, K.E.; Meffre, E.; et al. Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance. *J. Allergy Clin. Immunol.* **2008**, *23*, 1149–1161. [[CrossRef](#)]
- Weiskopf, D.; Sette, A. T-cell immunity to infection with dengue virus in humans. *Front. Immunol.* **2014**, *5*, 93. [[CrossRef](#)]

17. Jardim, D.L.F.; Tsukumo, D.M.L.; Angerami, R.N.; Filho, M.A.D.C.; Saad, M.J.A. Autoimmune features caused by dengue fever: A case report. *Braz. J. Infect. Dis.* **2012**, *16*, 92–95. [[CrossRef](#)]
18. Morel, Z.; Ramírez, A. Autoimmune Response in Children With Dengue. Case Reports. *Reumatol. Clín.* **2014**, *10*, 257–259. [[CrossRef](#)]
19. Rajadhyaksha, A.; Mehra, S. Dengue fever evolving into systemic lupus erythematosus and lupus nephritis: A case report. *Lupus* **2012**, *21*, 999–1002. [[CrossRef](#)]
20. Li, H.-M.; Huang, Y.-K.; Su, Y.-C.; Kao, C.-H. Increased risk of autoimmune diseases in dengue patients: A population-based cohort study. *J. Infect.* **2018**, *77*, 212–219.
21. García, G.; González, N.; Pérez, A.B.; Sierra, B.; Aguirre, E.; Rizo, D.; Izquierdo, A.; Sánchez, L.; Díaz, D.; Lezcay, M.; et al. Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. *Int. J. Infect. Dis.* **2011**, *15*, 38–43. [[CrossRef](#)] [[PubMed](#)]
22. Chien, Y.W.; Wang, C.C.; Wang, Y.P.; Lee, C.Y.; Perng, G.C. Risk of leukemia after dengue virus infection: A population-based cohort study. *Cancer Epidemiol. Biomark. Prev.* **2020**, *29*, 558–564. [[CrossRef](#)] [[PubMed](#)]
23. Chang, C.C.; Yen, Y.C.; Lee, C.Y.; Lin, C.F.; Huang, C.C.; Tsai, C.W.; Chuang, T.W.; Bai, C.H. Lower risk of primary Sjogren's syndrome in patients with dengue virus infection: A nationwide cohort study in Taiwan. *Clin. Rheumatol.* **2020**, 1–10. [[CrossRef](#)]
24. Lin, C.F.; Lei, H.Y.; Shiau, A.L.; Liu, C.C.; Liu, H.S.; Yeh, T.M.; Chen, S.H.; Lin, Y.S. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. *J. Med. Virol.* **2003**, *69*, 82–90. [[CrossRef](#)] [[PubMed](#)]
25. Chuang, Y.-C.; Lei, H.-Y.; Lin, Y.-S.; Liu, H.-S.; Wu, H.-L.; Yeh, T.-M. Dengue Virus-Induced Autoantibodies Bind to Plasminogen and Enhance Its Activation. *J. Immunol.* **2011**, *187*, 6483–6490. [[CrossRef](#)] [[PubMed](#)]
26. Chuang, Y.C.; Lin, Y.S.; Liu, H.S.; Wang, J.R.; Yeh, T.M. Antibodies against thrombin in dengue patients contain both anti-thrombotic and pro-fibrinolytic activities. *Thromb. Haemost.* **2013**, *110*, 358–365. [[CrossRef](#)]
27. Lin, C.F.; Lei, H.Y.; Liu, C.C.; Liu, H.S.; Yeh, T.M.; Wang, S.T.; Yang, T.I.; Sheu, F.C.; Kuo, C.F.; Lin, Y.S. Generation of IgM anti-platelet autoantibody in dengue patients. *J. Med. Virol.* **2001**, *63*, 143–149. [[CrossRef](#)]
28. Ojha, A.; Nandi, D.; Batra, H.; Singhal, R.; Annarapu, G.K.; Bhattacharyya, S.; Seth, T.; Dar, L.; Medigeshe, G.R.; Vrati, S.; et al. Platelet activation determines the severity of thrombocytopenia in dengue infection. *Sci. Rep.* **2017**, *7*, 1–10. [[CrossRef](#)]
29. Lin, C.-F.; Chiu, S.-C.; Hsiao, Y.-L.; Wan, S.-W.; Lei, H.-Y.; Shiau, A.-L.; Liu, H.-S.; Yeh, T.-M.; Chen, S.-H.; Liu, C.-C.; et al. Expression of Cytokine, Chemokine, and Adhesion Molecules during Endothelial Cell Activation Induced by Antibodies against Dengue Virus Nonstructural Protein 1. *J. Immunol.* **2005**, *174*, 395–403. [[CrossRef](#)]
30. Oishi, K.; Inoue, S.; Cinco, M.T.D.D.; Dimaano, E.M.; Alera, M.T.P.; Alfon, J.A.R.; Abanes, F.; Cruz, D.J.M.; Matias, R.R.; Matsuura, H.; et al. Correlation between increased platelet-associated IgG and thrombocytopenia in secondary dengue virus infections. *J. Med. Virol.* **2003**, *71*, 259–264. [[CrossRef](#)]
31. Liu, I.-J.; Chiu, C.-Y.; Chen, Y.-C.; Wu, H.-C. Molecular Mimicry of Human Endothelial Cell Antigen by Autoantibodies to Nonstructural Protein 1 of Dengue Virus. *J. Biol. Chem.* **2011**, *286*, 9726–9736. [[CrossRef](#)] [[PubMed](#)]
32. Falconar, A.K.I. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis. *Arch. Virol.* **1997**, *142*, 897–916. [[CrossRef](#)] [[PubMed](#)]
33. Tsai, C.L.; Sun, D.S.; Su, M.T.; Lien, T.S.; Chen, Y.H.; Lin, C.Y.; Huang, C.H.; King, C.C.; Li, C.R.; Chen, T.H.; et al. Suppressed humoral immunity is associated with dengue nonstructural protein NS1-elicited anti-death receptor antibody fractions in mice. *Sci. Rep.* **2020**, *10*, 1–13. [[CrossRef](#)] [[PubMed](#)]
34. Simon-Lorière, E.; Duong, V.; Tawfik, A.; Ung, S.; Ly, S.; Casadémont, I.; Prot, M.; Courtejoie, N.; Bleakley, K.; Buchy, P.; et al. Increased adaptive immune responses and proper feedback regulation protect against clinical dengue. *Sci. Transl. Med.* **2017**, *9*, eal5088. [[CrossRef](#)]
35. *WHO Dengue Guidelines for Diagnosis, Treatment, Prevention and Control*; Geneva World Health Organization Press: Geneva, Switzerland, 1997; Volume 6, pp. 39–48.
36. Zhu, H.; Luo, H.; Yan, M.; Zuo, X.; Li, Q.Z. Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus. *Genom. Proteom. Bioinforma.* **2015**, *13*, 210–218. [[CrossRef](#)]
37. Sfriso, P.; Ghirardello, A.; Botsios, C.; Tonon, M.; Zen, M.; Bassi, N.; Bassetto, F.; Doria, A. Infections and autoimmunity: The multifaceted relationship. *J. Leukoc. Biol.* **2010**, *87*, 385–395. [[CrossRef](#)]

38. Harel, M.; Shoenfeld, Y. Predicting and preventing autoimmunity, myth or reality? *Ann. N. Y. Acad. Sci.* **2006**, *1069*, 322–345. [[CrossRef](#)]
39. Montes, C.L.; Acosta-Rodríguez, E.V.; Merino, M.C.; Bermejo, D.A.; Gruppi, A. Polyclonal B cell activation in infections: Infectious agents' devilry or defense mechanism of the host? *J. Leukoc. Biol.* **2007**, *82*, 1027–1032. [[CrossRef](#)]
40. Racine, R.; Winslow, G.M. IgM in microbial infections: Taken for granted? *Immunol. Lett.* **2009**, *125*, 79–85. [[CrossRef](#)]
41. Changal, K.H.; Raina, A.H.; Raina, A.; Raina, M.; Bashir, R.; Latief, M.; Mir, T.; Changal, Q.H. Differentiating secondary from primary dengue using IgG to IgM ratio in early dengue: An observational hospital based clinico-serological study from North India. *BMC Infect. Dis.* **2016**, *16*, 1–7. [[CrossRef](#)]
42. Horns, F.; Dekker, C.L.; Quake, S.R. Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics. *Cell Rep.* **2020**, *30*, 905–913.e6. [[CrossRef](#)] [[PubMed](#)]
43. Gujarati, T.P.; Ambika, G. Virus antibody dynamics in primary and secondary dengue infections. *J. Math. Biol.* **2014**, *69*, 1773–1800. [[CrossRef](#)] [[PubMed](#)]
44. Patel, B.; Longo, P.; Miley, M.J.; Montoya, M.; Harris, E.; De Silva, A.M. Dissecting the human serum antibody response to secondary dengue virus infections. *PLoS Negl. Trop. Dis.* **2017**, *11*, 1–15. [[CrossRef](#)] [[PubMed](#)]
45. Vaughn, D.W.; Green, S.; Kalayanaraj, S.; Innis, B.L.; Nimmannitya, S.; Suntayakorn, S.; Endy, T.P.; Raengsakulrach, B.; Rothman, A.L.; Ennis, F.A.; et al. Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity. *J. Infect. Dis.* **2000**, *181*, 2–9. [[CrossRef](#)] [[PubMed](#)]
46. Halstead, S.B.; Nimmannitya, S.; Cohen, S.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. *Yale J. Boil. Med.* **1969**, *42*, 311–328.
47. Gunman, M.G.; Martweez, E.; Bravo, J. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). *Bull. Pan Am. Health Organ.* **1980**, *21*, 279.
48. Rivera-Correa, J.; Rodriguez, A. Divergent Roles of Antiself Antibodies during Infection. *Trends Immunol.* **2018**, *39*, 515–522. [[CrossRef](#)]
49. Nagele, E.P.; Han, M.; Acharya, N.K.; DeMarshall, C.; Kosciuk, M.C.; Nagele, R.G. Natural IgG Autoantibodies Are Abundant and Ubiquitous in Human Sera, and Their Number Is Influenced By Age, Gender, and Disease. *PLoS ONE* **2013**, *8*, e60726. [[CrossRef](#)]
50. Hue, K.D.T.; Tuan, T.V.; Thi, H.T.N.; Bich, C.T.N.; Le Anh, H.H.; Wills, B.A.; Simmons, C.P. Validation of an internally controlled one-step real-time multiplex RT-PCR assay for the detection and quantitation of dengue virus RNA in plasma. *J. Virol. Methods* **2011**, *177*, 168–173. [[CrossRef](#)]
51. Goldstein, L.D.; Chen, Y.J.J.; Wu, J.; Chaudhuri, S.; Hsiao, Y.C.; Schneider, K.; Hoi, K.H.; Lin, Z.; Guerrero, S.; Jaiswal, B.S.; et al. Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies. *Commun. Biol.* **2019**, *2*, 1–10. [[CrossRef](#)]
52. Jayathilaka, D.; Gomes, L.; Jeewandara, C.; Jayarathna, G.S.B.; Herath, D.; Perera, P.A.; Fernando, S.; Wijewickrama, A.; Hardman, C.S.; Ogg, G.S.; et al. Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection. *Nat. Commun.* **2018**, *9*, 1–15. [[CrossRef](#)] [[PubMed](#)]
53. Loizou, S.; Singh, E.; Wypkema, R.A.A. Anticardiolipin, anti-b2-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. *Ann. Rheum. Dis.* **2003**, *62*, 1106–1111. [[CrossRef](#)] [[PubMed](#)]
54. De Groot, P.G.; Urbanus, R.T. The significance of autoantibodies against β 2-glycoprotein I. *Blood* **2012**, *120*, 266–274. [[CrossRef](#)] [[PubMed](#)]
55. Kouser, L.; Abdul-Aziz, M.; Nayak, A.; Stover, C.M.; Sim, R.B.; Kishore, U. Properdin and factor H: Opposing players on the alternative complement pathway “see-saw”. *Front. Immunol.* **2013**, *4*, 93. [[CrossRef](#)] [[PubMed](#)]
56. Silveira, G.F.; Wowk, P.F.; Cataneo, A.H.D.; Dos Santos, P.F.; Delgobo, M.; Stimamiglio, M.A.; Lo Sarzi, M.; Thomazelli, A.P.F.S.; Conchon-Costa, I.; Pavanelli, W.R.; et al. Human T lymphocytes are permissive for dengue virus replication. *J. Virol.* **2018**, *92*, e02181-17. [[CrossRef](#)]
57. Agmon-Levin, N.; Damoiseaux, J.; Kallenberg, C.; Sack, U.; Witte, T.; Herold, M.; Bossuyt, X.; Musset, L.; Cervera, R.; Plaza-Lopez, A.; et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. *Ann. Rheum. Dis.* **2014**, *73*, 17–23. [[CrossRef](#)]

58. Koraka, P.; Suharti, C.; Setiati, T.E.; Mairuhu, A.T.A.; Van Gorp, E.; Hach, C.E.; Juffrie, M.; Sutaryo, J.; Van Der Meer, G.M.; Groen, J.; et al. Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. *J. Clin. Microbiol.* **2001**, *39*, 4332–4338. [[CrossRef](#)]
59. Yurasov, S.; Nussenzweig, M.C. Regulation of autoreactive antibodies. *Curr. Opin. Rheumatol.* **2007**, *19*, 421–426. [[CrossRef](#)]
60. Garcia-Carrasco, M.; Ramos, M.; Cervera, R.; Font, J.; Vidal, J.; Muñoz, F.J.; Miret, C.; Espinosa, G.; Ingelmo, M. Hepatitis C virus infection in “primary” Sjogren’s syndrome: Prevalence and clinical significance in a series of 90 patients. *Ann. Rheum. Dis.* **1997**, *56*, 173–175. [[CrossRef](#)]
61. Duong, V.; Lambrechts, L.; Paul, R.E.; Ly, S.; Lay, R.S.; Long, K.C.; Huy, R.; Tarantola, A.; Scott, T.W.; Sakuntabhai, A.; et al. Asymptomatic humans transmit dengue virus to mosquitoes. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 14688–14693. [[CrossRef](#)]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).